Dr. med. Melanie Hagen

Department of Medicine 3 – Rheumatology and Immunology

Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice (2024) Alsuliman T, Marjanovic Z, Rimar D, Tarte K, Avcin T, Hagen M, Schett G, Farge D Journal article, Review article Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells (2024) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Aigner M, Völkl S, et al. Journal article CD19-CAR T-cell therapy induces deep tissue depletion of B cells (2024) Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J, Bucci L, et al. Journal article Bispecific T cell engager therapy for refractory rheumatoid arthritis (2024) Bucci L, Hagen M, Rothe T, Raimondo MG, Fagni F, Tur C, Wirsching A, et al. Journal article CAR-T-Zell-Therapie in der Rheumatologie – Was wissen wir bisher? (2024) Hagen M, Wirsching A, Bohr D, Taubmann J, Müller F, Mackensen A, Grieshaber Bouyer R, Schett G Journal article Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial (2024) Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schönau V, Hueber A, et al. Journal article CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series (2024) Auth J, Müller F, Völkl S, Bayerl N, Distler JH, Tur C, Raimondo MG, et al. Journal article Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial (2023) Stephan M, Tascilar K, Yalcin-Mutlu M, Hagen M, Haschka J, Reiser M, Hartmann F, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution